| NTLA | Intellia Therapeutics Inc | 3.04% |
| ZLAB | Zai Lab Ltd ADR Repr 1 Shs | 2.99% |
| BBIO | BridgeBio Pharma Inc | 2.51% |
| FATE | Fate Therapeutics Inc | 2.25% |
| BEAM | Beam Therapeutics Inc | 2.22% |
| PACB | Pacific Biosciences of California Inc | 1.91% |
| TWST | Twist Bioscience Corp | 1.80% |
| HALO | Halozyme Therapeutics Inc | 1.78% |
| MEDP | Medpace Holdings Inc | 1.76% |
| VIR | Vir Biotechnology Inc | 1.70% |
The investment seeks to track the total return performance, before fees and expenses, of the NASDAQ Junior Biotechnology Index. The index is a rules-based index that consists of a portfolio of the stock of U.S.-listed small capitalization ("junior") companies screened from the universe of the NASDAQ Biotechnology Index. The fund will generally use a "replication" strategy to achieve its investment objective, meaning it will generally invest in all of the component securities of the index in the same approximate proportions as in the index. The fund is non-diversified.
Defiance Nasdaq Junior Biotechnology ETF
No recent news for IBBJ. The ingest cron pulls every 15 minutes during market hours.